health · family: the solution exists but nobody can afford it
adult pillsfor children's cancer
Fewer than 30% of children with cancer survive in most low- and middle-income countries, against over 80% in high-income countries, partly because chemotherapy drugs lack child-friendly formulations
Problem statement
Approximately 400,000 children and adolescents develop cancer each year. Survival in high-income countries exceeds 80%, but in most low- and middle-income countries it is below 30%. WHO calls the lack of age-appropriate medicines a significant barrier: for six priority oral cancer medicines that already have a paediatric indication, an optimal child-friendly formulation is missing. Children often rely on adult formulations that are difficult or impractical to administer: tablets are crushed or given on alternating-day schedules, or liquid preparations are compounded at home — leading to what WHO calls inaccurate dosing and unnecessary treatment risks, with compounded liquids limited by stability and crushed tablets posing inhalation hazards from airborne particles. In 2025, WHO published Target Product Profiles for child cancer drug formulations covering six priority agents (cyclophosphamide, etoposide, mercaptopurine, methotrexate, procarbazine, temozolomide); the formulations themselves do not yet exist, and WHO says they will be considered for its essential medicines list for children once they are developed and approved.
Why this matters
The WHO Global Initiative for Childhood Cancer targets a global survival rate of at least 60% by 2030, and WHO says the formulation work directly supports that goal. Liquid formulations — the default paediatric approach — can be chemically unstable (cyclophosphamide is inherently unstable in water, so WHO rules out liquid forms for it), often require refrigeration and have shorter shelf-lives, and are heavier and bulkier to transport than dispersible tablets. Crushed or broken tablets can release airborne particles of cytotoxic drug and contaminate surfaces, and the alternating-day schedules used to reach a child's dose from adult capsule sizes can confuse caregivers and increase the risk of error.
What’s been tried and why it hasn’t worked
The paediatric cancer formulation gap is at bottom a small-market problem: WHO describes medicines for children as fragmented, small markets, and childhood cancer as a broad category of distinct types, each with its own biology and clinical needs. Across disease areas, the development of medicines for children lags that for adults by around a decade. Liquid preparations have been attempted but are limited by stability, cold chain, palatability, and compounding challenges — five of the six priority drugs taste bitter or are likely to (cyclophosphamide and etoposide only slightly), procarbazine tastes slightly metallic, and high solubility can make taste problems worse because the drug dissolves in saliva. Taste masking is not free of trade-offs: coatings can cause cyclophosphamide to degrade during manufacturing, orodispersible films are sensitive to moisture, and if a dispersed dose sits too long before it is given, the drug can degrade and the taste masking can fail. WHO describes the markets for children's medicines as small and fragmented, and says urgent and concerted investment in R&D is needed.
What would unlock progress
The WHO TPPs specify dispersible or orodispersible tablets, minitablets, or multiparticulates as preferred forms — stable in hot/humid climates (30 degrees C / 75% relative humidity) with a shelf life over 24 months, no cold chain requirement, palatable taste profiles tested in validated assessments, and clear handling instructions for low-literacy settings. Solid oral forms were favoured for ease of administration and extended stability; dispersible tablets, taken in a 5-15 mL liquid or directly in the mouth, were considered suitable across a broad age range and come in pre-measured doses. For etoposide, the expert group identified minitablets of 1-3 mm or coated multiparticulates as the most swallowable form, with children over 6 months able to take them with food. The TPPs are written as recommendations to manufacturers and product development partnerships, and WHO intends to use them to encourage generic manufacturers through its expression-of-interest list — but WHO also says urgent and concerted investment in R&D is needed, and the products are not yet on the market.
Entry points for student teams
A team could formulate and stability-test a dispersible tablet or minitablet version of one WHO priority drug (e.g., mercaptopurine or methotrexate) under the hot/humid stability condition the WHO profiles target (Zone IVb, 30 degrees C / 75% RH), evaluating dissolution profile, chemical stability, and taste masking. The engineering challenge is maintaining dose uniformity and chemical stability in a solid form that disintegrates rapidly in the mouth. Alternatively, a team could conduct a comparative dosing accuracy study: crushed adult tablet vs. prototype dispersible formulation vs. liquid preparation, measuring the variance in delivered dose across simulated caregiver preparation scenarios. Relevant disciplines: pharmaceutical sciences, chemical engineering, paediatric oncology, formulation science.
Genes
Structural cousins: stuck the same way, in other fields
Sources
WHO, "Accelerating the development of priority formulations in childhood cancer: target product profiles for paediatric formulations of cyclophosphamide, etoposide, mercaptopurine, methotrexate, procarbazine, temozolomide," 2025, ISBN 9789240116092. WHO News, "WHO sets new global standard for child-friendly cancer drugs," Nov 6, 2025. go to source 1 ↗ go to source 2 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
- These TPPs follow WHO's January 2024 priority list of paediatric cancer formulations, which WHO calls its first-ever such list; WHO's paediatric drug optimization process had earlier been applied to HIV, hepatitis C, tuberculosis, antibiotics and neglected tropical diseases.
- The taste masking challenge interacts with the stability challenge in a way that makes formulation non-trivial: WHO notes that coating systems can degrade cyclophosphamide during manufacturing, that orodispersible films need careful handling of moisture sensitivity, and that a dispersed dose left standing can degrade and lose its taste masking.
- Structurally related to health-oxygen-concentrator-low-resource-failure (medical device/product designed for HIC conditions fails in LMIC context) but the constraint here is pharmaceutical rather than electromechanical.
Reconciliation 2026-09-30: Fact repair after reading the whole write-up against both sources it names, with a second reader going over every repair the same day. Both were fetched on 2026-09-30 directly from who.int: the WHO news item of 6 November 2025 (https://www.who.int/news/item/06-11-2025-who-sets-new-global-standard-for-child-friendly-cancer-drugs--paving-way-for-industry-innovation, read in full) and the TPP publication itself, downloaded as the 63-page PDF linked from the publication page (https://iris.who.int/server/api/core/bitstreams/84653039-d99e-4e99-8938-5dea9daa08ad/content, full text searched and the introduction, cross-cutting discussion, conclusions and the six drug chapters read). (1) The long title said children in low-income countries "die at 3x the rate" of high-income countries. Neither source gives a death-rate ratio; both give survival, over 80% in high-income settings and below 30% in most low- and middle-income countries. The title now states those two survival figures. Old title: "Children With Cancer in Low-Income Countries Die at 3x the Rate of High-Income Countries Partly Because Chemotherapy Drugs Lack Child-Friendly Formulations." New title: "Fewer Than 30% of Children With Cancer Survive in Most Low- and Middle-Income Countries, Against Over 80% in High-Income Countries, Partly Because Chemotherapy Drugs Lack Child-Friendly Formulations." (2) The Source line gave the publication's title as ending "procarbazine and temozolomide"; the publication page and the PDF's suggested citation end "procarbazine, temozolomide". The Source line now matches the record; ISBN and year were confirmed. (3) "Only 34% of oral childhood cancer medicines are available in paediatric-friendly formulations" is in neither source and was removed; the sentence now says what the TPP document says, that for six priority medicines with a paediatric indication an optimal formulation is missing. (4) "Clinicians in LMICs must crush adult tablets, split capsules, or compound liquid preparations — leading to imprecise dosing, chemical instability, and treatment failures": the document says capsules should not be manipulated, that tablets are often crushed or given on alternate schedules, that compounded suspensions are limited by stability, and that crushed tablets may release airborne particles; the news item says adult formulations lead to inaccurate dosing and unnecessary treatment risks. The sentence now says only that, without locating the practice in LMICs. (5) "Medicine availability in LMICs is rated 9-46% vs. 67-100% in HICs" is in neither source and was removed. (6) "Only 7% of pharma R&D in 2021 addressed needs of children under 12" is in neither source and was removed. (7) "Over 90% of pediatricians report drug taste/palatability as the greatest barrier" and "nearly 70% of anticancer APIs are bitter" are in neither source and were removed; the sentence now reports the tastes the TPP document gives for the six drugs. (8) "Paediatric formulations typically lag adult formulations by up to a decade" now says "by around a decade," the document's words (the news item says "nearly a decade"). (9) The GICC target was given as "60% survival in LMICs by 2030"; the document gives a global survival rate of at least 60% by 2030, and the sentence now says so. "Impossible without appropriate formulations" is not in the sources and now reads that WHO says the work directly supports the goal. (10) "First-ever Target Product Profiles" and the Source Note calling this "a new application of the TPP framework beyond infectious diseases": the news item applies "first-ever" to WHO's January 2024 priority list, not to the TPPs, and the document lists earlier paediatric drug optimization work on HIV, hepatitis C, TB, antibiotics and NTDs without calling those TPPs. Both sentences now say what the sources say. (11) "No manufacturer has yet developed products meeting these specifications" is not stated; the sources say an optimal formulation is missing and that the formulations will be considered for the essential medicines list once developed and approved, and the text now says that. (12) The liquid-formulation sentence said cyclophosphamide "degrades rapidly in water," that refrigeration is "unavailable in most LMIC supply chains," and that bulky packaging "increases shipping costs." The document says cyclophosphamide is inherently unstable in water so liquid forms are unsuitable, that syrups often require refrigeration and have shorter shelf-lives, and that dispersible tablets are lighter and more compact and cheaper to transport; the sentence now follows the document. (13) "Sedimentation in suspension, loss of active ingredient during crushing, and caregiver dosing mistakes," and "these errors have direct survival consequences," are not in the sources. The sentence now gives what the document says: crushed or broken tablets can release airborne cytotoxic particles and contaminate surfaces, and alternating-day schedules can confuse caregivers and increase error risk. (14) "Fundamentally a market failure," "tiny fraction of cancer patients," and "rare and biologically distinct from adult cancers" were softened to the document's own words: fragmented, small markets for children's medicines, and childhood cancer as a broad category of distinct types. The closing sentence of that section, which said the market was "too fragmented across LMICs to generate demand signals" and "too specialized for generic manufacturers to enter without clear specifications," now says only what the document says: small, fragmented markets and a need for urgent and concerted R&D investment. (15) "Sweeteners used for taste masking absorb moisture and compromise tablet stability in humid tropical climates" (body) and "many excipients that improve taste are hygroscopic" (Source Notes) are not in the sources; both now report what the document does say about coatings degrading cyclophosphamide, moisture sensitivity of orodispersible films, and degradation of a dispersed dose left standing. (16) The preferred forms now include multiparticulates, as the news item lists them; "orally disintegrating tablets that dissolve on contact with saliva are the emerging preferred platform" and "research has shown that even very young children can safely swallow appropriately sized minitablets" are not in the sources and were replaced by the document's statements that solid oral forms were favoured, that dispersible tablets in 5-15 mL or directly in the mouth suit a broad age range, and, in the etoposide chapter, that 1-3 mm minitablets or coated multiparticulates were identified as the most swallowable form, taken with food from 6 months of age. (17) The "demand signals" sentence now says the TPPs are recommendations to manufacturers and product development partnerships that WHO will use to encourage generic manufacturers through its expression-of-interest list, and that WHO calls for urgent R&D investment. (18) The first entry point proposed testing at 40 degrees C / 75% RH; the WHO profiles target Zone IVb, 30 degrees C / 75% relative humidity, and the entry point now names that condition. Confirmed in the sources and left as written: about 400,000 children (and adolescents, now added) developing cancer each year; survival over 80% versus below 30%; the six drug names; the 2025 date; the news item's title and date; the ISBN; the Global Initiative for Childhood Cancer; stability in hot and humid climates with a shelf life over 24 months, no cold chain, palatable taste, and clear instructions for low-literacy settings; the display title. Nothing was left unchecked, since both sources were read in full by both readers. Genome tags untouched.